Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 426811
Title Magnetic-Activated Cell Sorting of TCR-engineered T cells using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4 and CD8 T cells
Author(s) Govers, C.; Berrevoets, C.; Treffers-Westerlaken, E.; Broertjes, M.; Debets, R.
Source Human Gene Therapy Methods 23 (2012)3. - ISSN 1946-6536 - p. 213 - 224.
Publication type Refereed Article in a scientific journal
Publication year 2012
Keyword(s) adoptive transfer - metastatic melanoma - cancer regression - immune-responses - lymphocytes-t - antigen - therapy - generation - receptors - requires
Abstract T cell sorting technologies with peptide-MHC multimers or antibodies against gene markers enable enrichment of antigen-specific T cells and are expected to enhance therapeutic efficacy of clinical T cell therapy. However, a direct comparison between sorting reagents for their ability to enrich T cells is lacking. Here, we compared the in vitro properties of primary human T cells gene-engineered with gp100280-288/HLA-A2 specific TCRaß upon Magnetic Activated Cell Sorting (MACS) with different peptide-MHC multimers or an antibody against truncated CD34 (tCD34). With respect to peptide-MHC multimers, we observed that streptamers, when compared to pentamers and tetramers, improved T cell yield as well as level and stability of enrichment of TCR-engineered T cells (> 65% of peptide-MHC-binding T cells, stable for at least 6 weeks). In agreement with these findings, streptamers, the only detachable reagent, revealed significant T cell expansion in the 1st week after MACS. Sorting TCR and tCD34 gene-engineered T cells with CD34 mAb resulted in the most significant T cell yield and enrichment of T cells (> 95% of tCD34 T cells, stable for at least 6 weeks). Notably, T cells sorted with CD34 mAb, when compared to streptamer, bind about two to three-fold less peptide-MHC but show superior antigen-specific up-regulated expression of CD107a and production of IFN¿. Multi-parameter flow cytometry revealed that CD4 T cells, uniquely present in CD34 mAb-sorted T cells, contributed to enhanced IFN¿ production. Taken together, we postulate that CD34 mAb-based sorting of gene-marked T cells has benefits towards applications of T cell therapy, especially those that require CD4 T cells.
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.